Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Allison M WinterLisa RybickiShetal N ShahDeepa JagadeeshAaron T GerdsBetty K HamiltonHien LiuRobert DeanRonald SobecksBrad PohlmanMitchell SmithMatt KalaycioBrian J BolwellNavneet S MajhailBrian T HillPublished in: Leukemia & lymphoma (2017)
Pre-transplant PET/CT may be prognostic in diffuse large B-cell lymphoma (DLBCL) patients undergoing autologous stem cell transplantation (ASCT). We reviewed relapsed and pre-transplant PET/CT scans of 32 patients with DLBCL treated with ASCT to determine the Deauville score and the maximum standardized uptake value (SUVmax). Patients with a Deauville score of 4 had a significantly inferior prognosis. The 3-year progression-free survival (PFS) for patients with Deauville 1-3 score was 64%, compared to 0% for Deauville 4, while the 3-year overall survival (OS) was 84% and 25%, respectively (p < .001, p = .002). The change in the SUVmax (>66 versus ≤66%) was not predictive of PFS or OS, but a high pre-transplant SUVmax (>6) demonstrated a trend towards an inferior PFS. Pre-transplant PET/CT is a tool for identifying DLBCL patients at high risk for treatment failure with ASCT and could be used to risk-stratify patients in prospective clinical trials of novel transplant strategies.
Keyphrases
- pet ct
- diffuse large b cell lymphoma
- stem cell transplantation
- epstein barr virus
- positron emission tomography
- high dose
- end stage renal disease
- clinical trial
- newly diagnosed
- free survival
- chronic kidney disease
- patients undergoing
- ejection fraction
- bone marrow
- computed tomography
- prognostic factors
- low dose
- mesenchymal stem cells
- acute lymphoblastic leukemia
- cell therapy
- patient reported outcomes
- replacement therapy